Ischemic preconditioning in humans: Models, mediators, and clinical relevance

Circulation

Volumn 100, Issue 5, 1999, Pages 559-563

  Tomai, Fabrizio ^a   Crea, Filippo ^b   Chiariello, Luigi ^a   Gioffrè, Pier A ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Angina; Ischemia; Myocardial infarction

Indexed keywords

ADENOSINE; ADENOSINE DERIVATIVE; ADENOSINE RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; FIBRINOLYTIC AGENT; INSULIN; METHYLXANTHINE; POTASSIUM CHANNEL STIMULATING AGENT; SULFONYLUREA DERIVATIVE;

ADAPTATION; CLINICAL RESEARCH; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DILATATION; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HUMAN; IN VITRO STUDY; MODEL; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0033520027     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.5.559     Document Type: Review

References (44)

1. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986; 74:1124-1136.
2. Shiki K, Hearse DJ. Preconditioning of ischemic myocardium: reperfusion-induced arrhythmias. Am J Physiol. 1987;253:H1470-1476.
3. Cohen MV, Liu GS, Downey JM. Preconditioning causes improved wall motion as well as smaller infarcts after transient coronary occlusion in rabbits. Circulation. 1991;84:341-349.
4. Downey JM, Cohen MV. Mechanisms of preconditioning: correlates and epiphenomena. In: Marber MS, Yellon DM, eds. Ischemia: Preconditioning and Adaptation. Oxford, UK: BIOS Scientific Publishers Limited; 1996:21-34.
5. Yellon DM, Baxter GF. A. "second window of protection" or delayed preconditioning phenomenon: future horizons for myocardial protection? J Mol Cell Cardiol. 1995;27:1023-1034.
6. Vegh A, Papp JG, Parrat JR. Prevention by dexamethasone of the marked antiarrhythmic effects of preconditioning induced 20 h after rapid cardiac pacing. Br J Pharmacol. 1994;113:1081-1082.
7. Sun JZ, Tang XL, Knowlton AA, Park SW, Qiu Y, Bolli R. Late preconditioning against myocardial stunning: an endogenous protective mechanism that confers resistance to postischemic dysfunction 24 hours after brief ischemia in conscious pigs. J Clin Invest. 1995;95:388-403.
8. 3 receptors in protection of isolated human atrial muscle against simulated ischemia. Cardiovasc Res. 1997;36:52-59.
9. + channel? Studies of contractile function after simulated ischemia in an atrial in vitro model. Circ Res. 1995;77:1030-1035.
10. Cleveland JC, Meldrum DR, Cain BS, Banerjee A, Harken AH. Oral sulfonylurea hypoglicemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. Circulation. 1997;96: 29-32.
11. 2 receptor activation in human heart. J Am Coll Cardiol. 1997;29:1599-1606.
12. Yellon DM, Alkhulaifi AM, Pugsley WB. Preconditioning the human myocardium. Lancet. 1993;342:276-277.
13. Perrault LP, Menaschè P, Bel A, Dechaumaray T, Peynet J, Mondry A, Olivero P, Emanoilravier R, Moalic JM. Ischemic preconditioning in cardiac surgery: a word of caution. J Thorac Cardiovasc Surg. 1996;112: 1378-1386.
14. Jenkins DP, Pugsley WB, Alkhulaifi AM, Kemp M, Hooper J, Yellon DM. Ischemic preconditioning reduces troponin T release in patients undergoing coronary artery bypass surgery. Heart. 1997;77:314-318.
15. Mentzer RM, Rahko PS, Molina-Viamonte V, Canver CC, Chopra PS, Love RB, Cook TD, Hegge JO, Lasley RD. Safety, tolerance, and efficacy of adenosine as an additive to blood cardioplegia in humans during coronary artery bypass surgery. Am J Cardiol. 1997;79(12A): 38-43.
16. Menasché P, Jamieson WRE, Flameng W, Davis MK. Acadesine: a new drug that may improve myocardial protection in coronary artery bypass grafting (CABG). J Thorac Cardiovasc Surg, 1995;110:1096-1106.
17. Deutsch E, Berger M, Kussmaul WG, Hirshfeld JW, Herrmann HC, Laskey WK. Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic, and metabolic features. Circulation. 1990;82:2044-2051.
18. + channel blocker. Circulation. 1994;90:700-705.
19. Claeys MJ, Vrints CJ, Bosmans JM, Conraads VM, Snoeck JP. Aminophylline inhibits adaptation to ischemia during angioplasty. Role of adenosine in ischemic preconditioning. Ear Heart J. 1996;17:539-544.
20. 1 adenosine receptor blockade by bamiphylline on ischemic preconditioning during coronary angioplasty. Eur Heart J. 1996;17:846-853.
21. Leesar MA, Stoddard M, Ahmed M, Broadbent J, Bolli R. Preconditioning of human myocardium with adenosine during coronary angioplasty. Circulation. 1997;95:2500-2507.
22. Tomai F, Crea F, Gaspardone A, Versaci F, Ghini AS, De Paulis R, Chiariello L, Gioffrè PA. Phentolamine prevents adaptation to ischemia during coronary angioplasty. Role of α-adrenergic receptors in ischemic preconditioning. Circulation. 1997;96:2171-2177.
23. Tomai F. Ischemic preconditioning during coronary angioplasty. In: Marber MS, Yellon DM, eds. Ischemia: Preconditioning and Adaptation. Oxford, UK: BIOS Scientific Publishers Limited; 1996:163-185.
24. Kyriakidis MK, Petropoulakis PN, Tentolouris CA, Marakas SA, Antonopoulos AG, Kourouclis CV, Toutouzas PK. Relation between changes in blood flow of the contralateral coronary artery and the angiographic extent and function of recruitable collateral vessels arising from this artery during balloon coronary occlusion. J Am Coll Cardiol. 1994; 23:869-878.
25. Shattock MJ, Lawson CS, Hearse DJ, Downey JM. Electrophysiological characteristics of repetitive ischemic preconditioning in the pig heart. J Mol Cell Cardiol. 1996;28:1339-1347.
26. Cohen MV, Yang X, Downey JM. Attenuation of S-T segment elevation during repetitive coronary occlusions truly reflects the protection of ischemic preconditioning and is not an epiphenomenon. Basic Res Cardiol. 1997;92:426-434.
27. Xenopoulos NP, Leesar M, Bolli R. Morphine mimics ischemic preconditioning in human myocardium during PTCA. J Am Coll Cardiol. 1998; 31(suppl A):65A. Abstract.
28. Tomai F, Crea F, Gaspardone A, Versaci F, Ghini AS, Ferri C, Desideri GB, Chiariello L, Gioffrè PA. Effects of naloxone on myocardial ischemic preconditioning in man. Circulation. 1998;17:I-576-577. Abstract.
29. Okazaki Y, Kodama K, Sato H, Kitakaze M, Hirayama A, Mishima M, Hori M, Inoue M. Attenuation of increased regional myocardial oxygen consumption during exercise as a major cause of warm-up phenomenon. J Am Coll Cardiol. 1993;21:1597-1604.
30. Tomai F, Crea F, Danesi A, Perino M, Gaspardone A, Ghini AS, Cascarano MT, Chiariello L, Gioffrè PA. Mechanisms of the warm-up phenomenon. Eur Heart J. 1996;17:1022-1027.
31. 1 adenosine receptor blockade on the warm-up phenomenon. Cardiologia. 1997;42:385-392.
32. ATP channels with glibenclamide does not abolish preconditioning during demand ischemia. Am J Cardiol. 1997;79:75-78.
33. + channels prevents the warm-up phenomenon. Eur Heart J. 1997; 18:674. Abstract.
34. Kloner RA, Shook T, Przyklenk K, Davis VG, Junio L, Matthews RV, Burstein S, Gibson M, Poole WK, Cannon CP, McCabe CH, Braunwald E, for the TIMI4 investigators. Previous angina alters in hospital outcome in TIMI 4. A clinical correlate to preconditioning? Circulation. 1995;91: 37-47.
35. Andreotti F, Pasceri V, Hackett DR, Davies GJ, Haider AW, Maseri A. Preinfarction angina as a predictor of more rapid coronary thrombolysis in patients with acute myocardial infarction. N Engl J Med. 1996; 334:7-12.
36. Ishihara M, Sato H, Tateishi H, Kawagoe T, Shimatani Y, Kurisu S, Sakai K, Ueda K. Implications of prodromal angina pectoris in anterior wall acute myocardial infarction: acute angiographic findings and long-term prognosis. J Am Coll Cardiol. 1997;30:970-975.
37. Klimt CR, Knatterud GL, Meinen CL, Prout TE. A study of the effects of hypoglicemic agents on vascular complications in patients with adult-onset diabetes. Diabetes. 1970;19:747-830.
38. Rytter L, Troelsen S, Beck-Nielsen H. Prevalence and mortality of acute myocardial infarction in patients with diabetes. Diabetes Care. 1985;8: 230-234.
39. Mulcahy R, Al Awadhi AH, de Buitleor M, Tobin G, Johnson H, Contoy R. Natural history and prognosis of unstable angina. Am Heart J. 1985; 109:753-758.
40. Yang XM, Arnoult S, Tsuchida A, Cope D, Thornton JD, Daly JF, Cohen MV, Downey JM. The protection of ischaemic preconditioning can be reinstated in the rabbit heart after the initial protection has waned. Cardiovasc Res. 1993;27:556-558.
41. Tsuchida A, Thompson R, Olsson RA, Downey JM. The anti-infarct effect of an adenosine A1-selective agonist is diminished after prolonged infusion as is the cardioprotective effect of ischaemic preconditioning in rabbit heart. J Mol Cell Cardiol. 1994;26:303-311.
42. Dana A, Baxter GF, Walker JM, Yellon DM. Prolonging the delayed phase of myocardial protection: repetitive adenosine A1 receptor activation maintains rabbit myocardium in a preconditioned state. J Am Coll Cardiol. 1998;31:1142-1149.
43. Mahaffey KW, Puma JA, Barbagelata A, Casas CA, Lambe L, Orlandi C, Gibbons RJ, Califf RM, Granger CB. Does adenosine in conjunction with thrombolysis reduce infarct size? Results from the controlled, randomized AMISTAD Trial. Circulation. 1997;96(suppl I):I-206-207. Abstract.
44. Patel DJ, Purcell H, Wright C, Calrke D, Fox K, on behalf of the Nicorandil Unstable Angina Study Investigators. Nicorandil reduces myocardial ischaemia and tachyarrhythmias in unstable angina: results of a randomised placebo-controlled multicentre study. Eur Heart J. 1997; 18:165. Abstract.